These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 29066215)

  • 1. Treatment with long acting muscarinic antagonists stimulates serum levels of irisin in patients with COPD.
    Mandal J; Roth M; Papakonstantinou E; Sun Q; Costa L; Boeck L; Scherr A; Rakic J; Louis R; Milenkovic B; Boersma W; Kostikas K; Blasi F; Aerts J; Rohde G; Lacoma A; Torres A; Welte T; Tamm M; Stolz D
    Pulm Pharmacol Ther; 2018 Feb; 48():111-116. PubMed ID: 29066215
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative Effectiveness of Long-Acting Beta
    Samp JC; Joo MJ; Schumock GT; Calip GS; Pickard AS; Lee TA
    Pharmacotherapy; 2017 Apr; 37(4):447-455. PubMed ID: 28226405
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of Long-Acting Muscarinic Antagonist/Long-Acting β
    Petite SE
    Ann Pharmacother; 2017 Aug; 51(8):696-705. PubMed ID: 28410560
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A retrospective study to assess clinical characteristics and time to initiation of open-triple therapy among patients with chronic obstructive pulmonary disease, newly established on long-acting mono- or combination therapy.
    Mapel D; Laliberté F; Roberts MH; Sama SR; Sundaresan D; Pilon D; Lefebvre P; Duh MS; Patel J
    Int J Chron Obstruct Pulmon Dis; 2017; 12():1825-1836. PubMed ID: 28684905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of Cardiovascular and Cerebrovascular Events in COPD Patients Treated With Long-Acting β
    Samp JC; Joo MJ; Schumock GT; Calip GS; Pickard AS; Lee TA
    Ann Pharmacother; 2017 Nov; 51(11):945-953. PubMed ID: 28677404
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Irisin, a newly discovered myokine, is a novel biomarker associated with physical activity in patients with chronic obstructive pulmonary disease.
    Ijiri N; Kanazawa H; Asai K; Watanabe T; Hirata K
    Respirology; 2015 May; 20(4):612-7. PubMed ID: 25800067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative Cardiovascular and Cerebrovascular Safety of Inhaled Long-Acting Bronchodilators in Patients with Chronic Obstructive Pulmonary Disease: A Population-Based Cohort Study.
    Dong YH; Chang CH; Gagne JJ; Hsu CL; Lai MS
    Pharmacotherapy; 2016 Jan; 36(1):26-37. PubMed ID: 26799347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GOLD 2017 treatment pathways in 'real life': An analysis of the DACCORD observational study.
    Worth H; Buhl R; Criée CP; Kardos P; Lossi NS; Vogelmeier CF
    Respir Med; 2017 Oct; 131():77-84. PubMed ID: 28947047
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characteristics and health care resource use of subjects with COPD in the year before initiating LAMA monotherapy or LAMA+LABA combination therapy: A U.S. database study.
    Nagar S; Patel J; Stanford RH
    Manag Care; 2018 May; 27(5):40-47. PubMed ID: 29763411
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors influencing treatment escalation from long-acting muscarinic antagonist monotherapy to triple therapy in patients with COPD: a retrospective THIN-database analysis.
    Hurst JR; Dilleen M; Morris K; Hills S; Emir B; Jones R
    Int J Chron Obstruct Pulmon Dis; 2018; 13():781-792. PubMed ID: 29551894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A review of current and developing fixed-dose LABA/LAMA combinations for treating COPD.
    Lal C; Strange C
    Expert Opin Pharmacother; 2017 Dec; 18(17):1833-1843. PubMed ID: 29115881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rates of escalation to triple COPD therapy among incident users of LAMA and LAMA/LABA.
    Hahn B; Hull M; Blauer-Peterson C; Buikema AR; Ray R; Stanford RH
    Respir Med; 2018 Jun; 139():65-71. PubMed ID: 29858004
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential for long-acting muscarinic antagonists in chronic obstructive pulmonary disease.
    Joos GF
    Expert Opin Investig Drugs; 2010 Feb; 19(2):257-64. PubMed ID: 20047505
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preoperative management using inhalation therapy for pulmonary complications in lung cancer patients with chronic obstructive pulmonary disease.
    Takegahara K; Usuda J; Inoue T; Ibi T; Sato A
    Gen Thorac Cardiovasc Surg; 2017 Jul; 65(7):388-391. PubMed ID: 28281043
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characteristics, disease burden and costs of COPD patients in the two years following initiation of long-acting bronchodilators in UK primary care.
    Punekar YS; Landis SH; Wurst K; Le H
    Respir Res; 2015 Nov; 16():141. PubMed ID: 26572740
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhaled treatment of COPD: a Delphi consensus statement.
    Ninane V; Corhay JL; Germonpré P; Janssens W; Joos GF; Liistro G; Vincken W; Gurdain S; Vanvlasselaer E; Lehouck A
    Int J Chron Obstruct Pulmon Dis; 2017; 12():793-801. PubMed ID: 28293106
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysis.
    Rodrigo GJ; Price D; Anzueto A; Singh D; Altman P; Bader G; Patalano F; Fogel R; Kostikas K
    Int J Chron Obstruct Pulmon Dis; 2017; 12():907-922. PubMed ID: 28360514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Additive efficacy of short-acting bronchodilators on dynamic hyperinflation and exercise tolerance in stable COPD patients treated with long-acting bronchodilators.
    Kitaguchi Y; Fujimoto K; Komatsu Y; Hanaoka M; Honda T; Kubo K
    Respir Med; 2013 Mar; 107(3):394-400. PubMed ID: 23245993
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-acting Muscarinic Antagonist Versus Inhaled Corticosteroid when Added to Long-acting β-agonist for COPD: A Meta-analysis.
    Oba Y; Chandran AV; Devasahayam JV
    COPD; 2016 Dec; 13(6):677-685. PubMed ID: 27148815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LAMA/LABA vs ICS/LABA in the treatment of COPD in Japan based on the disease phenotypes.
    Hizawa N
    Int J Chron Obstruct Pulmon Dis; 2015; 10():1093-102. PubMed ID: 26089659
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.